0.3(top 100%)
impact factor
124(top 100%)
papers
123(top 50%)
citations
5(top 50%)
h-index
0.4(top 100%)
impact factor
152
all documents
129
doc citations
7(top 100%)
g-index

Top Articles

#TitleJournalYearCitations
1Socio-economic burden of COVID-19 in the Russian FederationKachestvennaya Klinicheskaya Praktika20207
2Socioeconomic and global burden of COVID-19Kachestvennaya Klinicheskaya Praktika20216
3Review of real-world data studyKachestvennaya Klinicheskaya Praktika20216
4Influence of dupilumab on the economic burden of severe asthma and atopic dermatitisKachestvennaya Klinicheskaya Praktika20206
5Use of unlicensed drugs and off-label drug use: focus on COVID-19Kachestvennaya Klinicheskaya Praktika20205
6Pragmatic clinical trialsKachestvennaya Klinicheskaya Praktika20204
7Risks associated with the ethical aspects of conducting clinical trialsKachestvennaya Klinicheskaya Praktika20204
8Oral anticoagulants in the prevention of thromboembolic complications in cardiac patients: analysis of use in the Russian FederationKachestvennaya Klinicheskaya Praktika20204
9The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitusKachestvennaya Klinicheskaya Praktika20213
10Drug-induced liver damage with cholestasisKachestvennaya Klinicheskaya Praktika20203
11Is it possible to use riamilovir to prevent infection and treat COVID-19?Kachestvennaya Klinicheskaya Praktika20203
12Current and future use of favipiravir in patients with COVID-19Kachestvennaya Klinicheskaya Praktika20203
13Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practiceKachestvennaya Klinicheskaya Praktika20203
14Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19Kachestvennaya Klinicheskaya Praktika20203
15Rationality of routine clinical use of olokizumab in COVID-19Kachestvennaya Klinicheskaya Praktika20203
16Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. PetersburgKachestvennaya Klinicheskaya Praktika20223
17Lifestyle Changes in Medical Students during the COVID-19 PandemicKachestvennaya Klinicheskaya Praktika20223
18Resource consumption and patient employability during systemic therapy and biological therapyKachestvennaya Klinicheskaya Praktika20212
19Applying real-world data to support regulatory decision — making in the United StatesKachestvennaya Klinicheskaya Praktika20212
20Ethical aspects of using software with artificial intelligence technologyKachestvennaya Klinicheskaya Praktika20212
21Pharmacoeconomic analysis of the choice of antimicrobial drugs for the treatment of community-acquired pneumonia by physicians and final year medical studentsKachestvennaya Klinicheskaya Praktika20212
22Current aspects of risk management in clinical trialsKachestvennaya Klinicheskaya Praktika20202
23Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm»Kachestvennaya Klinicheskaya Praktika20202
24Current and future use of colchicine in patients with COVID-19Kachestvennaya Klinicheskaya Praktika20202
25Multivariate analysis of medication adherence among outpatients with stable coronary artery diseaseKachestvennaya Klinicheskaya Praktika20222
26Nonsteroidal anti-inflammatory drugs’ adverse drug reactions: 10 years of national database dataKachestvennaya Klinicheskaya Praktika20222
27A logistic regression-based model to predict ICU mortality: problems and solutionsKachestvennaya Klinicheskaya Praktika20222
28Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillationKachestvennaya Klinicheskaya Praktika20232
29Effect of medication adherence on the risk of cardiovascular events in outpatients with stable coronary artery disease: results of two-year monitoringKachestvennaya Klinicheskaya Praktika20232
30Palliative care organization in the light of updated legislationKachestvennaya Klinicheskaya Praktika20211
31Th e clinical-economic analysis of Dupilumab in severe asthmaKachestvennaya Klinicheskaya Praktika20211
32Cystic fibrosis as a social-economic burdenKachestvennaya Klinicheskaya Praktika20211
33Legal aspects of conducting real-world studiesKachestvennaya Klinicheskaya Praktika20211
34Pharmacoeconomic feasibility of using Mirabegron in patients with overactive bladderKachestvennaya Klinicheskaya Praktika20211
35Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their baseKachestvennaya Klinicheskaya Praktika20211
36COVID-19: economic aspects of influenza vaccine preventionKachestvennaya Klinicheskaya Praktika20211
37Ethical aspects of the Internet of BodiesKachestvennaya Klinicheskaya Praktika20211
38Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2Kachestvennaya Klinicheskaya Praktika20201
39Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritisKachestvennaya Klinicheskaya Praktika20201
40Review of the European standard for postgraduate training of medical specialists in internal medicine and prospects for implementation in Russian FederationKachestvennaya Klinicheskaya Praktika20201
41Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancerKachestvennaya Klinicheskaya Praktika20201
42Clinical Pharmacology in Health Care, Teaching and ResearchKachestvennaya Klinicheskaya Praktika20201
43Analysis of the long-term effectiveness of a drug in the treatment of a chronic disease is the basis of rational pharmacotherapy (on the example of the use of roflumilast in the treatment of chronic obstructive pulmonary disease)Kachestvennaya Klinicheskaya Praktika20201
44Implementation of the concept of standard operating procedures into primary care practice: utopia or urgent need?Kachestvennaya Klinicheskaya Praktika20201
45Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumabKachestvennaya Klinicheskaya Praktika20201
46What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?Kachestvennaya Klinicheskaya Praktika20201
47Current and future use of umifenovir in patients with COVID-19Kachestvennaya Klinicheskaya Praktika20201
48Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and preventionKachestvennaya Klinicheskaya Praktika20201
49Current and future use of dipyridamole in patients with COVID-19Kachestvennaya Klinicheskaya Praktika20201
50Analysis of the effectiveness of the use of financial resources in the procurement of pharmaceuticals for state needsKachestvennaya Klinicheskaya Praktika20221